| Drug name | QX39 |
|---|---|
| Iupac name | N-(4-(6-chloroquinoxalin-2-yl)phenyl)acetamide |
| Cas number | 1798331-71-1 |
| Pubchem | 91809172 |
| C | 20 |
| H | 14 |
| Cl | 1 |
| N | 1 |
| O | 1 |
| Smiles | C1C(=NC2=C(O1)C=C(C=C2)Cl)C3=CC=C(C=C3)C4=CC=CC=C4 |
| Stdinchi | 1S/C20H14ClNO/c21-17-10-11-18-20(12-17)23-13-19(22-18)16-8-6-15(7-9-16)14-4-2-1-3-5-14/h1-12H,13H2 |
| Stdinchikey | RJFBVAUZKPHMJI-UHFFFAOYSA-N |
QX39 (Compound A, CA39) is a synthetic compound that activates chaperone-mediated autophagy (CMA) by increasing the expression of the lysosomal receptor for this pathway, LAMP2A lysosomes. It showed potent activity in vitro but has poor pharmacokinetic properties and was not suitable for animal research. Subsequent research led to the development of CA77.1, a CMA activator suitable for in vivo use.[1][2][3][4][5]
References
- ^ Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM (June 2013). "Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives". Nature Chemical Biology. 9 (6): 374–82. doi:10.1038/nchembio.1230. PMC 3661710. PMID 23584676
- ^ "Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof". No. 9512092.
- ^ "Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators". No. 2020077024.
- ^ Bourdenx M, Martín-Segura A, Scrivo A, Rodriguez-Navarro JA, Kaushik S, Tasset I, Diaz A, Storm NJ, Xin Q, Juste YR, Stevenson E, Luengo E, Clement CC, Choi SJ, Krogan NJ, Mosharov EV, Santambrogio L, Grueninger F, Collin L, Swaney DL, Sulzer D, Gavathiotis E, Cuervo AM (April 2021). "Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome". Cell. 184 (10): 2696–2714.e25. doi:10.1016/j.cell.2021.03.048. PMC 8152331. PMID 33891876
- ^ Cuervo AM, et al. Compounds Useful as Chaperone-Mediated Autophagy Modulators. Patent WO 2020/046335